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Abstract
Background: Epithelial ovarian cancer is a common malignancy, with no clinically approved diagnostic biomarker.
Engrailed-2 (EN2) is a homeodomain-containing transcription factor, essential during embryological neural
development, which is dysregulated in several cancer types. We evaluated the expression of EN2 in Epithelial
ovarian cancer, and reviewed its role as a biomarker.
Methods: We evaluated 8 Epithelial ovarian cancer cell lines, along with > 100 surgical specimens from the Royal
Surrey County Hospital (2009–2014). In total, 108 tumours and 5 normal tissue specimens were collected. En2
mRNA was evaluated by semi-quantitative RT-PCR. Histological sub-type, and platinum-sensitive/−resistant status
were compared. Protein expression was assessed in cell lines (immunofluorescence), and in > 150 tumours
(immunohistochemistry).
Results: En2 mRNA expression was elevated in serous ovarian tumours compared with normal ovary (p < 0.001),
particularly in high-grade serous ovarian cancer (p < 0.0001) and in platinum-resistant tumours (p = 0.0232). Median
Overall Survival and Progression-free Survival were reduced with high En2 expression (OS = 28 vs 42 months,
p = 0.0329; PFS = 8 vs 27 months; p = 0.0004). Positive cytoplasmic EN2 staining was demonstrated in 78% of
Epithelial ovarian cancers, with absence in normal ovary. EN2 positive high-grade serous ovarian cancer
patients had a shorter PFS (10 vs 17.5 months; p = 0.0103).
Conclusion: The EN2 transcription factor is a novel ovarian cancer biomarker. It demonstrates prognostic
value, correlating with worse Overall Survival and Progression-free Survival. It is hoped that further work will
validate its use as a biomarker, and provide insight into the role of EN2 in the development, progression and
spread of ovarian cancer.
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Background
Epithelial ovarian cancer (EOC) accounts for around 3%
of all female cancers, but is the most lethal of the female
reproductive tract cancers due to its predominantly
advanced stage at diagnosis.
The symptoms of ovarian cancer are often very vague
and may be misinterpreted as those of more common,
benign conditions. As these symptoms are mostly related
to the pressure effects of the growing tumour mass, they
may only present when the primary mass is already very
large, or when the disease has disseminated to the peri-
toneum. The only clinically utilised biomarker for EOC
is CA125, but this has not been approved for use in
diagnosis as it may be elevated in benign gynaecological
conditions such as endometriosis, and hence has a rela-
tively low sensitivity of 50–62% for early stage disease, al-
though this rises to 90% in advanced stage ovarian cancer
[1–3]. CA125 level after the first cycle of chemotherapy
and time to normalisation after the start of chemotherapy
can be useful as prognostic biomarkers [4, 5].
Many women with advanced EOC at diagnosis will
experience a good initial response to platinum-based
chemotherapy and surgery, and may have a prolonged
disease-free interval, but then often relapse with either
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local or distant disease. Although relapsed disease can
often be controlled with repeated platinum-based chemo-
therapy regimens, the progression-free relapse time inter-
val will eventually become less than 6 months, indicating
that the tumours have developed resistance to platinum.
There is a great deal of interest in biomarker research
in EOC especially for early diagnosis as the disease is
usually diagnosed at a late stage leading to a 5-year sur-
vival rate of only 30% for advanced-stage disease [6, 7].
In addition, there is increasing research into prognostic
and treatment response biomarkers, especially focussing
on the identification of molecular signatures that may
indicate the early development of platinum-resistant dis-
ease. The search for novel clinical biomarkers in EOC has
included analysis of various homeobox genes and their
protein products. The expression of HOXA9, HOXA10
and HOXA11 confers a serous, endometrioid and mucin-
ous phenotype respectively [8]. Kelly et al. also demon-
strated that high expression of HOXA13, B6, C13, D1 and
D13 were predictive of poor clinical outcome in EOC [9].
More recently, Miller et al demonstrated that HOXA4/
HOXB3 overexpression in high-grade serous ovarian can-
cer, correlated with a significantly shorter PFS, most likely
as a result of reduced platinum sensitivity [10]. PAX8, is
consistently over-expressed in high grade serous ovarian
carcinomas but negative in breast adenocarcinoma so is
often used by the pathologist to help determine the origin
of certain pelvic serous tumours, especially if the primary
tumour source is not always clearly evident [11–13].
Engrailed-2 (EN2) is a homeobox protein, essential dur-
ing embryological neural development and typically only
expressed in the normal adult Purkinje neurons and kid-
ney tubular epithelial cells. EN2 is dysregulated in several
cancer types, but at present there is no published data on
its presence in EOC. EN2 mRNA over-expression has
been demonstrated in breast and prostatic adenocarcin-
oma whilst it is not expressed in normal prostate and
breast tissue, or in benign disease [14, 15]. Secretion of
EN2 protein into the prostatic ductal lumen was also
noted, prompting further investigation of EN2 as a bio-
marker in prostate cancer. The presence of EN2 in urine
was highly predictive of prostate cancer, with a sensitivity
of 66% and specificity of 88.2% [15]. A linear relationship
between urinary EN2 and prostate cancer volume has
been demonstrated, along with a relationship between
urinary EN2 and tumour stage [16, 17]. Elevated levels of
urinary EN2 have also been detected in patients with
urothelial bladder cancer, with an overall sensitivity of
82% and specificity of 75% [18]. A study of 226 patients
with high grade urothelial bladder cancer showed that
EN2 expression in cancer was strongly predictive of poor
prognosis (manuscript in preparation).
Based on the paucity of diagnostic and prognostic bio-
markers in EOC, and the growing body of evidence that
EN2 has a role in other epithelial cancers, we evaluated
En2 gene and EN2 protein expression in a broad selec-
tion of EOC cell lines and human tumour tissues and
examined its relationship with clinical characteristics.
We hypothesised that over-expression of En2 mRNA
and EN2 protein in human EOC tumours, may prove
useful as a diagnostic, prognostic or treatment response
biomarker, helping to influence treatment decisions, and
ultimately improve overall survival rates.
Methods
Patients and controls
This study was approved by the London - Brighton & Sus-
sex Research Ethics Committee (REC no: 09/H1103/50)
and conducted between 2009 and 2014. Fresh ovarian
tissue was obtained from patients at The Royal Surrey
County Hospital, at the time of their primary surgery and
then stored in RNAlater™ (Sigma-Aldrich, UK) at − 20 °C.
In total 108 tumours and 5 normal tissue specimens were
collected. Normal human ovary RNA was purchased from
OriGene Technologies Inc., USA.
A separate cohort of 90 pre-cut slides from formalin-
fixed, paraffin embedded ovarian tumours were obtained
from The Royal Surrey County Hospital, along with
normal ovary and kidney slides as controls.
Human cell lines
All cell lines were obtained from the American Type Cul-
ture Collection (ATCC, USA), except for PEO1, PEO14
and PEO23 [Health Protection Agency (HPA, UK)], PEO4,
PEA1 and PEA2 (donated by Professor Hani Gabra at
Imperial College, University of London), and Fibroblasts
(donated by the University of Birmingham). All of the
human cell lines were adherent lines and were maintained
according to the supplied protocol. In the matched pairs,
the first set of cell lines (PEO1, PEO14, PEA1) were de-
rived following the patients’ diagnosis, while the second set
(PEO4, PEO23, PEA2) were derived following the onset
of acquired clinical platinum resistance. The normal
human skin fibroblast cell line was used as a negative
control and the melanoma cell line, A375M, was used
as a positive control.
RNA extraction & cDNA synthesis from cell lines & human
tumours
Total RNA was extracted from cell lines and homogenised
tumours using the RNeasy® Plus Mini Kit (Qiagen, UK)
according to the manufacturer’s instructions. Extracted
RNA was eluted in RNase-free water and quantified using
a Nanodrop ND-1000 Spectrophotometer. cDNA was
synthesised from total RNA using the Cloned AMV First
Strand cDNA Synthesis Kit (Invitrogen, UK) following the
manufacturer’s protocol, using 1 μg of RNA. cDNA
samples were stored at − 20 °C (10 ng/μl).
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Semi-quantitative RT-PCR
Semi-quantitative RT-PCR was performed using the
Stratagene MX3005P Real Time PCR machine (Agilent
Technologies, UK), measuring PCR product accumula-
tion during the exponential phase of the reaction by
SYBR green fluorescence (SYBR® Green JumpStart™ Taq
ReadyMix™ Kit, Sigma-Aldrich, UK). Reaction conditions
were 1 cycle of 94 °C for 10 min, 40 cycles of 30 s at
94 °C, and 1 min at 60 °C and 30 s at 72 °C. The forward
and reverse primers for En2 were 5′ GAACCCGAA
CAAAGAGGACA 3′ and 5′ CGCTTGTTCTGGAA
CCAAAT 3′, and for ß-actin were 5′ ATGTA CCCT
GGCATTGCCGACA 3′ and 5′ GACTCGTCATACTC
CTGCTTGT 3′. Relative expression was calculated
using the ΔCT comparative method (2
-ΔCt) [15, 18],
and expression is shown relative to ß-actin (× 100,000).
Enzymatic immunofluorescent staining on cell lines
Cell lines were incubated for monolayer growth in
8-chambered polystyrene culture treated glass slides
(BD Biosciences, UK) with appropriate media. Staining
was compared in the absence of primary antibody, and in
non-permeabilised and permeabilised cells (0.2% Triton
X-100 (Sigma-Aldrich, UK). Cells were incubated in
5 μg/ml Wheat-Germ Agglutinin cell membrane stain
(Invitrogen, UK) for 10 min at 37 °C, before fixation
with warm 4% paraformaldehyde, and blocking with 4%
horse serum. Cells were incubated overnight in poly-
clonal goat anti-EN2 antibody (Abcam, UK) diluted
1:100 in 1% BSA (Sigma-Aldrich, UK) in PBS or in 1%
BSA in PBS alone. This primary antibody has been used
within the department for immunofluorescence work in
multiple cells lines derived from varying tumour types,
with consistent results. The secondary antibody Alexa
Fluor 488 donkey anti-goat IgG (Invitrogen, UK) di-
luted 1:200 in 1% BSA/PBS was added, along with the
nuclear stain TO-PRO-3 (Life Technologies, UK) diluted
1:400, at room temperature for 1 h. The slides were
mounted and visualised using a Zeiss LSM 510 confocal
laser scanning microscope, and a Plan-Apochromat
40× oil immersion objective. Images were recorded
and analysed using ZEN 2009 capture software.
Enzymatic immunohistochemistry on patient slides and
tissue arrays
Following the deparaffinisation and rehydration of slides,
the heat mediated antigen retrieval method was utilised,
using citrate buffer (10 mM, pH 6.0). Polyclonal rabbit
anti-EN2 antibody (LS-B3477, LifeSpan Biosciences,
Seattle, USA,) was diluted 1:20 in 1% BSA in PBS and
applied overnight. 1% BSA in PBS alone was added to
control slides. The bound primary antibody was detected
using the R.T.U. VECTASTAIN ABC Kit (Vector Labora-
tories, USA) followed by DAB detection. Slides were
counterstained with Haematoxylin and mounted. The
Royal Surrey County Hospital Pathology Department
performed automated Haematoxylin & Eosin (H&E)
staining on adjacent sections.
Slides were scored by two independent investigators for
immuno-intensity of EN2 staining: 0, negative; 1, weak; 2,
moderate; 3, strong. The percentage of immuno-positive
cells was also recorded and scored from 1 to 4. The prod-
uct of immuno-intensity and immuno-positivity ranged
from 0 to 12, with 0–4 representing EN2 negative staining,
and 5–12 representing EN2 positive staining [19]. All
slides were reviewed by an independent gynaecological
pathologist.
Statistical analysis
The GraphPad Prism software package was used to con-
struct graphs and for statistical calculations. The signifi-
cance level for all tests was set at 5%. The following
symbols were used in diagrams/figures to denote levels
of significance: -.* = p < 0.05; ** = p < 0.01; *** = p < 0.001;
**** = p < 0.0001.
The one-way ANOVA with Bonferroni correction was
performed for En2 mRNA expression cell line data,
using the mean CT value relative to ß-actin [20–22]. For
the different histological sub-types of human tumour tis-
sue, the non-parametric Kruskal Wallis test with Dunn’s
correction was used. For comparison of two groups, the
non-parametric Mann-Whitney U-test was used.
Comparative analysis of EN2 positive and negative
tumour sections and tissue cores was conducted using
the Chi-squared test [23].
All survival analyses were performed using the Log-rank
(Mantel Cox) test.
Results
EN2 expression in epithelial ovarian cancer cell lines
RNA was extracted from cultures of 8 serous EOC cell
lines, with the platinum-sensitivity status recorded for
each of these. PEO1 represented a cell line derived from
a platinum-sensitive, serous ovarian carcinoma. The
PEO4 cell line was derived from the same patient, once
they had developed platinum-resistant disease. Similarly,
PEO14 and PEO23, and PEA1 and PEA2, were paired
cell lines derived from the same patient before and after
developing platinum-resistant disease.
Evaluation of the EOC cell lines revealed En2 expres-
sion in the majority of cell lines, but to a varying degree
(Fig. 1). The serous EOC lines PEO4 and PEA2 dem-
onstrated significantly higher En2 expression than
fibroblasts (p < 0.0001 and p < 0.01 respectively). The
platinum-sensitive/resistant paired serous cell lines
all showed elevated En2 expression, however there was a
significant increase in the platinum-resistant lines, com-
pared with their platinum-sensitive pairings. This was
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most notable with the PEO1/PEO4 (p < 0.0001) and
PEA1/PEA2 (p < 0.05) paired cell lines.
For assessment of EN2 protein in EOC cell lines, en-
zymatic immunofluorescent staining was performed.
This analysis demonstrated that EN2 protein was
present in all of the EOC cell lines tested, in particular
the paired platinum sensitive/insensitive cell lines, and
the A375M melanoma cells, whilst it was not detectable
in the normal skin fibroblast cell line (Fig. 2a). EN2
appeared to be predominantly expressed within the cyto-
plasm of the cancer cell lines, especially after the cells
were permeabilised. There was no co-localisation of nu-
clear and EN2 protein staining to suggest the presence
of nuclear EN2 in any of the cell lines stained (Fig. 2b).
Co-localisation of cell membrane and EN2 protein stain-
ing suggested that EN2 is located in close proximity to
the cell membrane (Fig. 2c).
EN2 expression in human ovarian tissue
We subsequently analysed 108 tumour samples, repre-
senting a variety of EOC histological sub-types (Table 1).
All serous ovarian and peritoneal tumours were grouped
together as “pelvic serous carcinoma”, a term suggested by
Nik et al. [24]. The relative expression of En2 in normal
ovary was very low in comparison to that of the malignant
tumour samples. Although higher than the normal speci-
mens, the En2 expression in benign and borderline epithe-
lial tumours was also much lower than the malignant
tumours. En2 expression in the serous ovarian group was
significantly elevated in comparison to the normal speci-
men group (p < 0.001), namely > 1200-fold higher, and this
was maintained when the serous ovarian and peritoneal
groups were combined as the “pelvic serous carcinoma”
group (p < 0.005) (Fig. 3a). High-grade serous ovarian car-
cinomas (HGSOC) are the most common histological
presentation in the clinic, and represented 97% of the
pelvic serous tumours within this data set. En2 ex-
pression in the HGSOC group was again significantly
elevated in comparison to the normal specimen group
(p < 0.0001) (Fig. 3b).
Platinum-based chemotherapy treatment data was avail-
able for 75 of the high-grade serous epithelial tumours,
including progression-free survival, which allowed us to
determine the platinum-sensitivity-status of the tu-
mours as defined by Blackledge [25]. En2 expression
was higher in platinum-resistant tumours compared to
those that were platinum-sensitive, particularly when
considering those patients who had already received
some chemotherapy prior to surgery, i.e. the interval
surgery cohort (Fig. 3c and d); p = 0.0232).
Survival analyses of the HGSOCs were performed
based on low versus high En2 mRNA expression. As
En2 expression had not previously been evaluated in
ovarian cancer, we had little guide as to what constituted
low or high expression, so we defined low expression as
a CT value relative to ß-actin < 1000, and high expression
as > 1000. This took into consideration, the fact that all
borderline, benign and normal ovarian tissue had mean
CT values relative to ß-actin < 100. When analysing the
HGSOC “interval surgery specimens”, both the median
overall survival (OS) and median progression-free survival
(PFS) in the high En2 group were significantly lower than
in the low En2 group (28 vs 42 months for OS; p = 0.0329
(Fig. 3e), and 9 vs 18 months for PFS; p = 0.0036 (Fig. 3f)).
This difference in PFS was even more pronounced
when considering only the interval surgical HGSOCs
(8 vs 27 months; p = 0.0004 (Fig. 3g)).
The prevalence and expression pattern of EN2 was
also assessed at the protein level in two separate co-
horts of patient tumours which enabled the combined
Fig. 1 En2 mRNA expression in EOC cell lines and controls. Eight ovarian cancer cell lines were analysed by quantitative RT-PCR. Fibroblasts were
used as a negative control and the A375M cell line as a positive control. En2 mRNA expression is shown relative to β-actin (× 100,000), using the
ΔCT comparative method (2
-ΔCt). Error bars represent the SD (n = 3) (* = p < 0.05; ** = p < 0.01; **** = p < 0.0001)
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analysis of a large number of EOC specimens (111
HGSOCs in total). The summary demographic data for
these cohorts are shown in Tables 1 and 2. Examples of
the EN2 protein expression in human ovarian tissue are
shown in Fig. 4.
Positive cytoplasmic EN2 staining was demonstrated
in 78% of EOCs and over 65% of borderline tumours,
whilst there was no staining in the majority of benign
tumours and in all normal ovary specimens. Compara-
tive analysis of the tumour sections confirmed a
A
B
C
Fig. 2 EN2 expression via immunofluorescent staining of platinum-sensitive/−resistant paired serous ovarian cancer cell lines and controls. (a) EN2
fluorescent staining (green) was present in the cytoplasm of the serous cell lines, particularly evident in those that had been permeabilised. There
was no EN2 staining evident in the permeabilised negative control of each cell line, where only secondary antibody was added (inset). There was
no EN2 staining evident in the fibroblast cell line, whilst there was strong cytoplasmic staining in the melanoma A375M positive control cell line.
TOPRO staining (blue) identified the cell nucleus and WGA staining (red) identified the cell membrane. Co-localisation of cell membrane WGA
and EN2 protein staining (yellow) can be seen in some of the non-permeabilised cells (blue arrows). (b) Intensity profiles for each label along the
length of the white arrow are shown in a PEA2 cell, and a PEO4 cell (c), demonstrating the absence of EN2 in the nucleus, but close association
with the cell membrane. The coloured peaks represent the cell membrane, nucleus, presence of EN2, and co-localisation of EN2 with the cell
membrane, as detailed above
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significant difference between EOC and borderline tu-
mours compared to benign and normal samples
(Table 3). Patients with HGSOC tumours staining posi-
tive for EN2 had a significantly shorter median PFS than
those with EN2 negative tumours (10 vs 17.5 months; p
= 0.0103) (Fig. 4i). This difference is similar to that ob-
served for En2 mRNA expression. There was no signifi-
cant difference in OS between the groups.
Confirmatory immunohistochemical staining of three
ovarian cancer tissue arrays was performed to confirm
the findings in our patient cohorts, and again demon-
strated high levels of EN2 protein staining in EOC cores,
particularly the serous histological sub-type (data not
shown). As with our patient analysis, there was no EN2
staining in the epithelial or stromal components of
normal ovary or normal adjacent ovary tissue.
Discussion
Despite significant advances in the medical management
of solid tumours over the past decade, there has been
little impact on the survival of advanced EOC. CA125
remains the only approved serum biomarker in ovarian
cancer, however its routine use is restricted to monitoring
ovarian cancer progression and treatment response. Other
mucin-related glycoproteins such as MUC1 (CA15–3),
HE4 and mesothelin have been extensively studied, alone
or in combination with CA125, but still lack the de-
sired high sensitivity and specificity necessary for a
gold-standard clinical biomarker [26–29].
Many developmental homeodomain-containing tran-
scription factors are aberrantly expressed in cancer and
have been shown to promote cancer development, pro-
gression, recurrence or development of drug resistance
[30, 31]. EN2 encodes a transcription factor that plays an
important role in embryonic development, but appears
to have limited function in the normal adult nervous
system [32, 33]. EN2 over-expression has been identified
in a number of adult human cancers, namely breast,
prostate, and bladder, and appears to have a functional
role in tumour development. In EOC, the homeobox
transcription factors HOXA13, B6, C13, D1 and D13
may be useful as prognostic biomarkers in EOC [9], and
PAX8 is regularly used as a contributory diagnostic bio-
marker in EOC [11–13]. Preliminary work on cell lines
and tissue arrays suggested that EN2 may be present in
ovarian cancer [34]. To test its role as a diagnostic or
prognostic biomarker, En2 RNA and protein expression
in EOC cell lines and tumour tissue was characterised
and its relationship with clinico-pathological parameters
was assessed.
We demonstrated En2 mRNA and EN2 protein over-ex-
pression in a number of EOC representative cell lines, and
observed significantly higher En2 mRNA expression in
platinum-resistant compared with paired platinum-sensi-
tive cells. However this was not seen in other examples of
serous and endometrioid platinum-resistant cell lines.
Some of these discrepancies may be as a result of
inaccurate histological sub-type labelling. In a recent pub-
lication it was reported that the well-used SKOV3 cell line,
previously thought to represent a high grade serous
ovarian cancer, is actually more in keeping with an
endometrioid pathology on molecular analysis [35].
EN2 protein was detectable via immunohistochemis-
try in all of the cell lines to a varying degree but when
quantified its expression was found to be higher in plat-
inum-sensitive compared to platinum-resistant paired
cell lines. Although cell line work can be very inform-
ative and guide on-going work, it is not always fully
representative of what occurs in the human tumour in
vivo, especially if derived from ascitic fluid or meta-
static tumour deposits rather than the primary tumour.
Similar work on human tumour samples was vital to
draw more comprehensive conclusions regarding EN2
expression in EOC.
Table 1 Summary data from the human ovarian tumours Cohort 1
Histology N Mean age
(range)
Median
Grade
Median
Stage
Surgery
(Number of patients)
Platinum Status
(Number of patients)
Median
PFS
Median
OS
Primary Interval Sensitive Resistant
Pelvic serous carcinoma 75 65.28 (40–86) 3 3 22 53 56 17 10 31
Serous adenocarcinoma 58 65.60 (42–86) 3 3 20 38 43 14 10 32
Primary peritoneal adenocarcinoma 17 64.47 (40–74) 3 3 2 15 13 3 10 34
Endometrioid adenocarcinoma 8 61.63 (45–84) 3 3 7 1 5 2 11 30.5
Mucinous adenocarcinoma 2 54 (48–60) 3 3 1 1 0 1 1 6.5
Clear cell carcinoma 4 49(40–62) 3 3 4 0 1 2 1 14
MMMT 6 72.50 (62–90) 3 3 5 1 0 3 1.5 5
Borderline epithelial tumour 8 56 (36–69) – – 8 0 – – – –
Benign tumour 5 55.2 (48–68) – – – – – – – –
Normal ovary 5 67.58 (54–84) – – – – – – – –
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En2 mRNA expression in ovarian tissue could provide
useful clinical information, although its use as a diagnostic
marker of EOC would seem to be limited. EN2 protein
levels in high-grade serous tumours was much higher than
in normal ovarian specimens, and very low in non-
invasive borderline and benign serous ovarian tumours. It
may also help to provide an early indication of whether
the original tumour derives from the ovary or peritoneum,
given that En2 mRNA levels for the latter group were
lower. At present, the primary source of the cancer is
A
C
E
G
F
B
D
Fig. 3 En2 mRNA expression is elevated in high-grade serous tumours, with higher expression conveying poor prognosis. Malignant, borderline,
benign and normal tumours were analysed, with mean En2 mRNA expression for each histological sub-type (a), or high grade serous tumours
(HGSOCs) and non-malignant specimens (b), shown. Follow-up data was studied to determine if the patient had platinum-resistant (PFS <
6 months) or platinum-sensitive (PFS≥ 6 months) disease. En2 mRNA expression is shown for all HGSOCs (c), and interval surgery HGSOCs versus
platinum status (d)(p = 0.0232). Survival curves compare high versus low En2 expression for (e) overall survival in interval surgery HGSOCs (median
OS = 28 vs. 42 months; p = 0.0329), (f) progression-free survival in all HGSOC specimens (median PFS = 9 vs. 18 months; p = 0,0036), and (g)
progression-free survival in interval surgery HGSOCs (median PFS = 8 vs. 27 months; p = 0.0004). `En2 mRNA expression is shown relative to β-
actin (× 100,000), using the ΔCT comparative method (2
-ΔCt). Error bars represent the SE; (* = p < 0.05; ** = p < 0.01;
*** = p < 0.001; **** = p < 0.0001)
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often not confirmed until primary or interval-debulking
surgery has been completed. EN2 protein staining was
also detected in the majority of EOC and borderline
tumour specimens, and was negative in all normal ovary
specimens, and in most benign tumours. However the
intensity of staining did not reliably distinguish between
the histological sub-type, grade, or stage of disease.
Our findings indicate that En2 mRNA expression could
act as a prognostic biomarker in interval debulking sur-
gery in high-grade serous EOC tissue where an elevated
level predicted a shorter PFS. Elevated En2 mRNA levels
also suggested a shorter OS, further supporting its pos-
sible use as a prognostic biomarker, although 40% of the
OS data remained censored at the time of analysis. There
Table 2 Summary data from the human ovarian tumours Cohort 2
Histology N Mean age
(range)
Median
Grade
Median
Stage
Surgery
(Number of patients)
Platinum Status
(Number of patients)
Median
PFS
Median
OS
Primary Interval Sensitive Resistant
Pelvic serous carcinoma 44 60.18 (25–81) 3 3 30 14 33 5 13.5 41
Endometrioid adenocarcinoma 12 63 (44–84) 2 1 12 0 10 0 97 105
Mucinous adenocarcinoma 6 64.67 (42–84) 3 3 6 0 1 2 1 9.5
Clear cell carcinoma 1 58 3 3 1 0 – – 1 1
MMMT 3 71.67 (69–75) 3 3 2 1 – 2 1.5 5
Borderline epithelial tumour 17 54.18 (25–89) – – 17 0 – – – –
Benign tumour 7 64.86 (46–80) – – 7 0 – – – –
Fig. 4 EN2 protein expression in human ovarian tissue conveys poor prognosis. Enzymatic immunohistochemistry examples of normal
kidney (a), normal ovary with surface epithelium (b) and ovarian adenocarcinoma stained for EN2 (c, e, g), or adjacent sections stained for
H&E (d, f, h), at 10× magnification. The assigned staining intensity (1–3+) is indicated. EN2 staining (brown) is present in the cytoplasm,
but not in the nucleus, and is not seen in the surrounding stroma. On the H&E stained sections, pink staining represents cytoplasm and
blue staining represents the nucleus. (i) Survival curves for EN2 negative versus EN2 positive protein expression in high-grade serous
ovarian tumours are shown (EN2 -ve = 0–4 IHC score; EN2 + ve = 5–12 IHC score). The median survival was significantly lower for all
HGSOCs with EN2 + ve staining (10 months) versus those with EN2 –ve staining (17.5 months) (p = 0.0103)
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is growing data to suggest that a number of homeobox
transcription factors may play a prognostic role in serous
ovarian cancer [9, 10]. Therefore combining these HOX
genes with EN2 expression, may also prove useful as a
scoring system for prognostic risk stratification.
EN2 protein analysis of interval debulking surgery
high-grade serous tumour specimens also demonstrated
its possible utility as a prognostic biomarker. Patients with
EN2-positive tumours had a shorter PFS, with durations
in keeping with the mRNA data. However, there were no
Table 3 EN2 protein expression in human ovarian tissue (Cohorts 1 and 2)
The product of the EN2 staining intensity score (0–3+) and the percentage of positively stained cells score (0–4) was calculated. The resultant score of 0–4
represented EN2 negative staining, and 5–12 represented EN2 positive staining. Comparative analysis of the tumour sections demonstrated a significant difference
between the EOC and borderline tumours, compared with the benign and normal tissues (x2 = 26.854, p < 0.001)
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significant differences in OS. Given that interval debulking
surgery with pathological analysis is commonplace in
the management of high-grade serous EOC, evaluation
of En2 mRNA or EN2 protein expression could help
the oncologist to devise a more individualised post-opera-
tive treatment regimen. An elevated En2 tumour mRNA
level at interval debulking surgery in high-grade serous
EOC patients was associated with early disease relapse,
suggesting resistance to platinum chemotherapy. In com-
bination with the surgeon’s assessment of the amount of
residual disease at debulking surgery, the level of En2
mRNA could be used to assess treatment response, and
guide the oncologist in deciding whether to prescribe
additional cycles of post-operative chemotherapy, or to
change the combination of drugs.
Increased En2 mRNA and EN2 protein expression
were identified in platinum-resistant EOC cell line
models and human tissue samples compared with
platinum-sensitive cases. In the case of the paired EOC
cell lines, this suggested that increased En2 expression
may directly influence the disease progression or the de-
velopment of platinum-resistance. We demonstrated
that EN2 protein was located in the cytoplasm of EOC
cell lines and tumour tissue, and not the nucleus, as seen
in normal adult Purkinje neurones. This may suggest
that it has a role in translational, rather than transcrip-
tional regulation, possibly through a similar mechanism
to that demonstrated in neurons of the developing ner-
vous system [36]. In certain cell lines, it was visualised in
association with the cell membrane, which may relate to
cellular secretion or uptake.
An ideal early diagnostic biomarker would be a sero-
logical or urine-based biomarker which enables minim-
ally invasive collection and low cost. Unfortunately, EN2
has proven difficult to isolate in blood (personal com-
munication with Prof Richard Morgan), and although
detectable in urine in known ovarian cancer sufferers,
additional work is required to assess its utility.
Conclusion
This original research presents the Engrailed-2 transcription
factor as a novel ovarian cancer biomarker. EN2 demon-
strates prognostic value, particularly in interval debulking
high-grade serous EOC tissue, correlating with worse over-
all and progression-free survival. Clearly, there is still an un-
met need for robust diagnostic, as well as prognostic
biomarkers in EOC. Therefore, it is hoped that further work
will validate the use of EN2 as a such a biomarker, and pro-
vide further insight into the role of EN2 in the develop-
ment, progression and spread of ovarian cancer.
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